Bp annual total liabilities
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bp Total Liabilities Growth & History (BP.)
Bp's total liabilities was $204.53B for fiscal 2025.
View full Bp company overviewBp annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $204.53B | $616.0M | +0.30% |
| 2024 | 2024-12-31 | $203.91B | $9.11B | +4.68% |
| 2023 | 2023-12-31 | $194.80B | −$10.33B | −5.04% |
| 2022 | 2022-12-31 | $205.13B | $8.30B | +4.22% |
| 2021 | 2021-12-31 | $196.83B | $14.75B | +8.10% |
| 2020 | 2020-12-31 | $182.09B | −$12.40B | −6.38% |
| 2019 | 2019-12-31 | $194.49B | $13.86B | +7.67% |
| 2018 | 2019-01-01 | $180.63B | $4.52B | +2.56% |
| 2017 | 2017-12-31 | $176.11B | $9.64B | +5.79% |
| 2016 | 2016-12-31 | $166.47B | — | — |
Bp quarterly total liabilities
Q4.16
Q4.17
Q2.18
As of Dec 31, 2018
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $218.21B | $13.25B | +6.46% |
| Q1 2026 | 2026-03-31 | $224.78B | — | — |
| Q4 2025 | 2025-12-31 | $204.53B | $616.0M | +0.30% |
| Q3 2025 | 2025-09-30 | $202.81B | — | — |
| Q2 2025 | 2025-06-30 | $204.96B | $13.77B | +7.20% |
| Q4 2024 | 2024-12-31 | $203.91B | $9.11B | +4.68% |
| Q2 2024 | 2024-06-30 | $191.19B | $721.0M | +0.38% |
| Q4 2023 | 2023-12-31 | $194.80B | −$10.33B | −5.04% |
| Q2 2023 | 2023-06-30 | $190.46B | −$27.11B | −12.46% |
| Q4 2022 | 2022-12-31 | $205.13B | $8.30B | +4.22% |
| Q2 2022 | 2022-06-30 | $217.57B | $26.72B | +14.00% |
| Q4 2021 | 2021-12-31 | $196.83B | $14.75B | +8.10% |
| Q2 2021 | 2021-06-30 | $190.85B | $10.48B | +5.81% |
| Q4 2020 | 2020-12-31 | $182.09B | −$12.40B | −6.38% |
| Q2 2020 | 2020-06-30 | $180.37B | −$9.17B | −4.84% |
| Q4 2019 | 2019-12-31 | $194.49B | — | — |
| Q2 2019 | 2019-06-30 | $189.54B | $15.68B | +9.02% |
| Q4 2018 | 2019-01-01 | $180.63B | $4.52B | +2.56% |
| As of Dec 31, 2018 | 2018-12-31 | $180.63B | $4.52B | +2.56% |
| Q2 2018 | 2018-06-30 | $173.86B | — | — |
| Q4 2017 | 2017-12-31 | $176.11B | $9.64B | +5.79% |
| Q4 2016 | 2016-12-31 | $166.47B | — | — |
Bp total liabilities trends
Over the last five fiscal years, Bp's total liabilities increased from $182.09B to $204.53B, a change of $22.44B. The latest reported quarter, Q2 2026, shows $218.21B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bp source filings ↗Community posts
BP strengthens its balance sheet after quarterly underlying profit reaches $8.46 billion
BP ($BP) reported third-quarter 2026 underlying replacement-cost profit of $8.458 billion, compared with $2.210 billion a year earlier and $5.732 billion in the previous quarter. Higher refining margins and stronger trading supported earnin ...
BP reportedly reviews a possible sale of Brazilian biofuels business
BP is considering options for its Brazilian biofuels operations, including a possible sale, according to a Bloomberg report cited by Reuters. The account relies on people familiar with the matter, and Reuters said it could not immediately v ...
BP agrees to sell a 5% Browse gas-project interest to Osaka Gas
Osaka Gas agreed to buy a 5% interest in Australia’s Browse gas project from BP ($BP) through an entity jointly owned with JOGMEC. The price was not disclosed. The transaction requires regulatory and partner approvals. Browse remains in pre ...
